UA89618C2 - 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы - Google Patents
6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразыInfo
- Publication number
- UA89618C2 UA89618C2 UAA200603730A UAA200603730A UA89618C2 UA 89618 C2 UA89618 C2 UA 89618C2 UA A200603730 A UAA200603730 A UA A200603730A UA A200603730 A UAA200603730 A UA A200603730A UA 89618 C2 UA89618 C2 UA 89618C2
- Authority
- UA
- Ukraine
- Prior art keywords
- quinoxalinones
- quinolinones
- adp
- ribose
- poly
- Prior art date
Links
- -1 6-substituted 2-quinolinones Chemical class 0.000 title 1
- 229940127397 Poly(ADP-Ribose) Polymerase Inhibitors Drugs 0.000 title 1
- FFRYUAVNPBUEIC-UHFFFAOYSA-N quinoxalin-2-ol Chemical class C1=CC=CC2=NC(O)=CN=C21 FFRYUAVNPBUEIC-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012661 PARP inhibitor Substances 0.000 abstract 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Psychology (AREA)
- Structural Engineering (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078859 | 2003-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA89618C2 true UA89618C2 (ru) | 2010-02-25 |
Family
ID=34639300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200603730A UA89618C2 (ru) | 2003-12-05 | 2004-11-18 | 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7879857B2 (ru) |
| EP (1) | EP1709012B1 (ru) |
| JP (1) | JP4806353B2 (ru) |
| KR (1) | KR101159118B1 (ru) |
| CN (1) | CN1890224B (ru) |
| AU (1) | AU2004295059B2 (ru) |
| BR (1) | BRPI0416532A (ru) |
| CA (1) | CA2546657C (ru) |
| EA (1) | EA010488B1 (ru) |
| ES (1) | ES2551299T3 (ru) |
| IL (1) | IL176060A (ru) |
| NO (1) | NO20063028L (ru) |
| NZ (1) | NZ547193A (ru) |
| SG (1) | SG151249A1 (ru) |
| UA (1) | UA89618C2 (ru) |
| WO (1) | WO2005054210A1 (ru) |
| ZA (1) | ZA200604549B (ru) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ546990A (en) | 2003-11-20 | 2010-03-26 | Janssen Pharmaceutica Nv | 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| SG150533A1 (en) | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| UA91007C2 (ru) * | 2003-12-10 | 2010-06-25 | Янссен Фармацевтика Н.В. | Замещенные 6-циклогексилалкилом замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли-(адф-рибоза)полимеразы |
| ATE444068T1 (de) * | 2004-01-23 | 2009-10-15 | Janssen Pharmaceutica Nv | Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren |
| AU2005259189B2 (en) | 2004-06-30 | 2011-04-21 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as PARP inhibitors |
| WO2006003148A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Quinazolinedione derivatives as parp inhibitors |
| CN1976906B (zh) | 2004-06-30 | 2010-09-01 | 詹森药业有限公司 | 用作parp抑制剂的取代2-烷基喹唑啉酮衍生物 |
| NZ587586A (en) | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
| JO2952B1 (en) * | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| WO2008030891A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| AU2007305269A1 (en) * | 2006-10-04 | 2008-04-10 | Schering Corporation | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
| JP5545955B2 (ja) * | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| NZ586125A (en) | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| AU2009228945B2 (en) | 2008-03-27 | 2013-05-02 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
| JP5492183B2 (ja) | 2008-03-27 | 2014-05-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| EP2760854B1 (en) * | 2011-09-30 | 2017-08-30 | Asana BioSciences, LLC | Imidazole derivatives as cyp17 inhibitors for the treatment of cancer |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| HK1213250A1 (zh) | 2012-10-16 | 2016-06-30 | Janssen Pharmaceutica, N.V. | RORγT的雜芳基連接的喹啉基調節劑 |
| ES2628365T3 (es) | 2012-10-16 | 2017-08-02 | Janssen Pharmaceutica N.V. | Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T |
| KR20150070347A (ko) | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | Ror-감마-t의 메틸렌 결합 퀴놀리닐 조절제 |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| KR20160068956A (ko) | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | RORyT의 퀴놀리닐 조절제 |
| AU2014334619A1 (en) | 2013-10-15 | 2016-04-21 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORyt |
| LT3325623T (lt) | 2015-07-23 | 2019-10-25 | Inst Curie | Dbait molekulės ir parp inhibitorių derinio panaudojimas vėžiui gydyti |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| MA46779A (fr) | 2016-11-02 | 2019-09-11 | Health Research Inc | Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3615026B1 (en) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| CN109081828B (zh) * | 2017-06-14 | 2021-03-26 | 上海时莱生物技术有限公司 | 聚(adp-核糖)聚合酶抑制剂、制备方法及用途 |
| US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
| PT3999506T (pt) | 2019-07-19 | 2025-04-09 | Astrazeneca Ab | Inibidores da parp1 |
| EP4065099A4 (en) | 2019-11-25 | 2023-11-29 | The Research Foundation for The State University of New York | COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANS FOR THE TREATMENT OF CANCER |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN118804916B (zh) * | 2022-01-21 | 2025-04-01 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3274194A (en) * | 1963-03-29 | 1966-09-20 | Miles Lab | Quinazolinedione derivatives |
| GB1293565A (en) * | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| US3919425A (en) * | 1971-04-09 | 1975-11-11 | Miles Lab | Method of producing vasodilation using certain 3-substituted-quinazoline derivatives |
| DE2355084A1 (de) * | 1972-11-06 | 1974-05-16 | Guidotti & C Spa Labor | Verbindungen mit magensaeuresekretionshemmender wirkung und verfahren zu deren herstellung |
| US3879393A (en) * | 1973-06-18 | 1975-04-22 | Miles Lab | Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones |
| US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| US5231184A (en) * | 1987-11-23 | 1993-07-27 | Janssen Pharmaceutica N.V. | Pridazinamine derivatives |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| KR0149162B1 (ko) * | 1988-11-29 | 1998-10-15 | 구스타프 반 리이트 | (1h-아졸-1-일메틸) 치환된 퀴놀린, 퀴나졸린 또는 퀴녹살린 유도체 |
| CA2002864C (en) * | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| GB8827822D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| US5374637A (en) * | 1989-03-22 | 1994-12-20 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
| IE913473A1 (en) * | 1990-10-15 | 1992-04-22 | Fujisawa Pharmaceutical Co | Quinazoline derivatives and their preparation |
| NZ251610A (en) * | 1992-04-23 | 1996-02-27 | Merrell Dow Pharma | 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions |
| JPH06239858A (ja) * | 1993-02-16 | 1994-08-30 | Otsuka Pharmaceut Co Ltd | 末梢血管拡張剤 |
| NZ334543A (en) * | 1996-09-10 | 2000-06-23 | Thomae Gmbh Dr K | Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays |
| US6417362B1 (en) * | 1997-05-30 | 2002-07-09 | Meiji Seika Kaisha, Ltd. | Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same |
| US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US20030069231A1 (en) * | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| US7265115B2 (en) * | 1999-01-29 | 2007-09-04 | Abbott Laboratories | Diazabicyclic CNS active agents |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6723733B2 (en) * | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
| US7115630B2 (en) * | 2000-10-02 | 2006-10-03 | Janssen Pharmaceutica N.V. | Metabotropic glutamate receptor antagonists |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1396488A1 (en) * | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| WO2003000266A1 (en) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinolines and uses thereof |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| ATE540928T1 (de) * | 2002-11-22 | 2012-01-15 | Mitsubishi Tanabe Pharma Corp | Isochinolinverbindungen und ihre medizinische verwendung |
| NZ546990A (en) * | 2003-11-20 | 2010-03-26 | Janssen Pharmaceutica Nv | 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| SG150533A1 (en) * | 2003-11-20 | 2009-03-30 | Janssen Pharmaceutica Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| DE102004023332A1 (de) * | 2004-05-12 | 2006-01-19 | Bayer Cropscience Gmbh | Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung |
| WO2006003148A1 (en) * | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Quinazolinedione derivatives as parp inhibitors |
| JP5075624B2 (ja) * | 2005-04-28 | 2012-11-21 | 田辺三菱製薬株式会社 | シアノピリジン誘導体及びその医薬としての用途 |
| US8198448B2 (en) * | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8466150B2 (en) * | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| WO2009002469A1 (en) * | 2007-06-25 | 2008-12-31 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
-
2004
- 2004-11-18 SG SG200901531-4A patent/SG151249A1/en unknown
- 2004-11-18 EP EP04819602.6A patent/EP1709012B1/en not_active Expired - Lifetime
- 2004-11-18 NZ NZ547193A patent/NZ547193A/en not_active IP Right Cessation
- 2004-11-18 JP JP2006541830A patent/JP4806353B2/ja not_active Expired - Fee Related
- 2004-11-18 UA UAA200603730A patent/UA89618C2/ru unknown
- 2004-11-18 AU AU2004295059A patent/AU2004295059B2/en not_active Ceased
- 2004-11-18 CA CA2546657A patent/CA2546657C/en not_active Expired - Fee Related
- 2004-11-18 WO PCT/EP2004/013164 patent/WO2005054210A1/en not_active Ceased
- 2004-11-18 US US10/596,086 patent/US7879857B2/en not_active Expired - Fee Related
- 2004-11-18 EA EA200601100A patent/EA010488B1/ru not_active IP Right Cessation
- 2004-11-18 KR KR1020067011234A patent/KR101159118B1/ko not_active Expired - Fee Related
- 2004-11-18 BR BRPI0416532-2A patent/BRPI0416532A/pt not_active Application Discontinuation
- 2004-11-18 ES ES04819602.6T patent/ES2551299T3/es not_active Expired - Lifetime
- 2004-11-18 CN CN2004800358571A patent/CN1890224B/zh not_active Expired - Fee Related
-
2006
- 2006-05-31 IL IL176060A patent/IL176060A/en not_active IP Right Cessation
- 2006-06-02 ZA ZA2006/04549A patent/ZA200604549B/en unknown
- 2006-06-28 NO NO20063028A patent/NO20063028L/no not_active Application Discontinuation
-
2010
- 2010-12-17 US US12/971,319 patent/US20110230491A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL176060A (en) | 2012-10-31 |
| NZ547193A (en) | 2010-03-26 |
| CN1890224B (zh) | 2011-06-08 |
| CA2546657C (en) | 2013-05-14 |
| CN1890224A (zh) | 2007-01-03 |
| US20110230491A1 (en) | 2011-09-22 |
| KR20060118534A (ko) | 2006-11-23 |
| AU2004295059B2 (en) | 2010-12-16 |
| JP4806353B2 (ja) | 2011-11-02 |
| JP2007513101A (ja) | 2007-05-24 |
| EA010488B1 (ru) | 2008-10-30 |
| CA2546657A1 (en) | 2005-06-16 |
| AU2004295059A1 (en) | 2005-06-16 |
| KR101159118B1 (ko) | 2012-06-22 |
| SG151249A1 (en) | 2009-04-30 |
| ZA200604549B (en) | 2008-04-30 |
| EP1709012A1 (en) | 2006-10-11 |
| US7879857B2 (en) | 2011-02-01 |
| HK1098150A1 (en) | 2007-07-13 |
| EP1709012B1 (en) | 2015-07-29 |
| ES2551299T3 (es) | 2015-11-17 |
| US20070129375A1 (en) | 2007-06-07 |
| BRPI0416532A (pt) | 2007-01-09 |
| NO20063028L (no) | 2006-06-28 |
| IL176060A0 (en) | 2006-10-05 |
| EA200601100A1 (ru) | 2006-10-27 |
| WO2005054210A1 (en) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA89618C2 (ru) | 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы | |
| SG151250A1 (en) | Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors | |
| UA91002C2 (ru) | 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы | |
| SG154433A1 (en) | Phthalazine derivatives as parp inhibitors | |
| MY169515A (en) | Quinazolinedione derivatives as parp inhibitors | |
| SG154434A1 (en) | Quinazolinone derivatives as parp inhibitors | |
| UA91027C2 (ru) | ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53 | |
| WO2004074244A3 (en) | Pyrimidine compounds | |
| NO20062894L (no) | 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer | |
| SE0101675D0 (sv) | Novel composition | |
| TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| WO2004106293A3 (en) | Oxazolyl - and thiazolyl - purine based tricyclic compounds. | |
| GB0308201D0 (en) | Novel compounds | |
| SE0303541D0 (sv) | New compounds | |
| WO2004075846A3 (en) | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | |
| WO2007120333A3 (en) | Tetracyclic kinase inhibitors | |
| WO2005011609A3 (en) | Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | |
| TW200740816A (en) | P38 MAP kinase inhibitors and methods for using the same | |
| WO2008098077A3 (en) | Substituted alkine derivatives as anti-cancer agents | |
| MY154363A (en) | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors | |
| UA86777C2 (en) | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors | |
| MXPA06000988A (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| DE60220504D1 (en) | Tryptasehemmer |